Year: 2021
Type: article
Study design: Observational Study
Abstract: Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum amyloid A [SAA]) and/or the presence of a high-risk IL-6 promoter genotype were associated with recurrence of hormone receptor positive (HR+) early breast cancer. Estrogen levels were also measured and correlated with biomarkers and disease outcomes. CRP and SAA were significantly associated with an increased risk of recurrence in the HR+/HER2- group, but not the HR+/HER2+ group. Mean serum estrogen levels were non-significantly elevated in patients who relapsed vs. non-relapsed patients. Surprisingly, high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse, which has potential therapeutic implications, as elevated intracellular IL-6 has been associated with trastuzumab resistance in pre-clinical models.
Source: npj Breast Cancer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,170
Funders: U.S. Department of Health and Human Services, Susan G. Komen for the Cure, University of Pennsylvania, Susan G. Komen, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Environmental Health Sciences, Center of Excellence in Environmental Toxicology, University of Pennsylvania
Awards: G1007166040, Estrogen Deprivation and Aromatase Inhibitor associated Arthralgia, G3977186708, G5523352432, G7543532892, G8249158751, G9000174336, Cancer Center Support Grant, Translational Research Training Program in Environmental Health Sciences, IRACDA at the University of Pennsylvania: Penn Postdoctoral Opportunities in Research and Teaching (PennPORT)., Center of Excellence in Environmental Toxicology, Cancer Clinical Epidemiology Training Grant, Abramson Cancer Center Support Grant
OpenAlex ID: W3122152282